The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

The Effects and Safety of Cardiotonic Pills with Pletaal on Post-Reperfusion Syndrome of Arteriosclerotic Occlusive Disease(Pilot Study)

  • Jang, Woo-Seok (College of Korean Medicine, Daegu Haany University) ;
  • Kwak, Min-Ah (College of Korean Medicine, Daegu Haany University) ;
  • Park, Ki-hyuk (College of Medicine, Daegu Catholic University)
  • Received : 2016.11.01
  • Accepted : 2016.12.27
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The patients who had arteriosclerotic occlusive disease were treated by reperforating procedures or vessel replacing operations. We divided them by two groups. one(control group) is treated by Pletaal(cilostazole), the other(CP group) is by Pletaal with cardiotonic pills(CP). Methods : Control group was treated by Pletaal, CP group was treated by Pretaal with CP for 8 weeks. We primarily evaluated the outcomes by visual analogue scale(VAS) of pain, coldness, numbness, and edema, secondarily hematologic tests. Results : Coldness, numbness and edema were reduced at both groups. In CP group, the VAS dropped more sharply than control group, but not significant. Otherwise, there was significant reduction of VAS on pain. In hematologic tests, there were no abnormal results of all items. Conclusion : The therapy of Pletaal with CP is effective to relieve PRS specially in pain and safety on hematologic tests.

Keywords

References

  1. Park SH, Youm W. Clinical Analysis of Arterial Bypass on the Atherosclerotic Occlusive Disease in Lower Extremities. Korean J Thorac Cardiovasc Surg. 1997;30:195-199.
  2. Shin YC, Kim MJ, Song CM, Ahn JB, Kim IS, Kim WS, et al. The Use of Greater Saphenous Vein in Situ Graft in Arterial Occlusive Disease of Lower Extremity. Korean J Thorac Cardiovasc Surg. 2006;39:456-461.
  3. Chung SW, Kim JW. Occlusive Complications after Lower Limb Arterial Bypass Surgery. Korean J Thorac Cardiovasc Surg. 2005;38:152-156.
  4. Falconer TM, Eikelboom JW, Hankey GJ, Norman PE. Management of pheripheral arterial disease in the elderly : focus on cilostazol. Clinical Interventions in Aging. 2008;3(1):17-23. https://doi.org/10.2147/CIA.S1735
  5. O'Donnell ME, Bader SA, Sharif MA, Makar RR, McEneny J, Young IS, et al. The Effects of Cilostazol on Exercise-induced Ischaemia-reperusion Injury in Patients with Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2009;37:326-335. https://doi.org/10.1016/j.ejvs.2008.11.028
  6. Jang IS, Ko CN, Lee I, Park JM, Kim SH, Kim SW. Effect of Carditonic Pills on Chest Pain and Discomfort : A Multi-center Double-blind Randomized Controlled Trial. J Korean Oriental Med. 2005;26(2):95-104.
  7. Kwon TW, Son YS, Cho SI, Kim YK. Protective Effects of Cardiotonic Pills(CP) on Neuroglia Cells Against Oxidative Stress and the Effects on Regional Cerebral Blood Flow in Normal Rats. Kor. J Herbology. 2008;23(4):71-79.
  8. Kim HW, Kwon TW, Jung Sun, Cho SI, Kim YG, Bong SJ. Effects of Cardiotonic Pills(CP) on Serum Lipid Level in Hyperlipidemic Rats. Kor. J Herbology. 2008;23(2):145-150.
  9. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee Bernard, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49:1226-1234. https://doi.org/10.1016/j.jvs.2008.11.098
  10. Thompson PD, Zimet Richard, Forbes WP, Zhang Peter. Meta-Analysis of Results from Eight Randomized, Placebo-Controlled Trials on the Effect of Cilostazol on Patients With Intermittent Claudication. The American Journal of Cardiology. 2002;90:1314-1319. https://doi.org/10.1016/S0002-9149(02)02869-2
  11. Hiatt W, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease : The CASTLE study. Journal of Vascular Surgery. 2008;47(2):330-336. https://doi.org/10.1016/j.jvs.2007.10.009
  12. Kim E. Pharmacokinetics Interaction between Cardiotonic Pills and Cilostazol in Rats. Journal of Life Science. 2016;26(1):123-128. https://doi.org/10.5352/JLS.2016.26.1.123